| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3293090 | Gastroenterology | 2012 | 9 Pages |
Abstract
In HBeAg-negative patients with CHB, it is safe and effective to discontinue ADV therapy after 4 or 5 years; 55% of patients have sustained responses, and 39% of patients lose HBsAg.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Stephanos J. Hadziyannis, Vassilios Sevastianos, Irene Rapti, Dimitrios Vassilopoulos, Emilia Hadziyannis,